logo
logo

Harrow Acquires Santen’S Branded Ophthalmic Portfolio

Jul 18, 2023•about 2 years ago

Acquiring Company

Harrow

Acquired Company

Portfolio

NashvillePharmaceuticalBiotechnologyHealth Care

Description

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:

Company Information

Company

Harrow

Location

Nashville, Tennessee, United States

About

Harrow (NASDAQ: HROW) is a growing leader in the ophthalmic healthcare market. Our mission as a growing leader in the ophthalmic healthcare market is driven by two core values: (1) unyielding dedication to innovation and (2) a mission of providing affordable and accessible medications. We pride ourselves on closely listening to the needs of providers and their patients, so we can do everything in our power to address them with high-quality products and services. Our worthwhile mission is producing amazing financial results, and because we’ve produced a 72% compound annual growth rate for our first eight years in business, we are one of the fastest-growing ophthalmic pharmaceutical companies in the United States.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed